Albert Bourla's banner

Albert Bourla

@AlbertBourla • 240,375 subscribers

Chairman and CEO of @Pfizer. Father. 🇬🇷🇺🇸 Working every day for breakthroughs that change patients’ lives.

Shorts

Great news from our team to start the week: positive Phase 2 results for a potential first-in-class medicine discovered and developed entirely in-house at Pfizer Inc.. It has the potential to work differently from anything available today, targeting three drivers of inflammation in a single treatment. This could make a real difference for millions of people living with conditions like atopic dermatitis, COPD, and asthma. We're accelerating toward Phase 3 and excited about what lies ahead. This is the kind of innovation our pipeline is built to deliver. More:

Great news from our team to start the week: positive Phase 2 results for a potential first-in-class medicine discovered and developed entirely in-house at Pfizer Inc.. It has the potential to work differently from anything available today, targeting three drivers of inflammation in a single treatment. This could make a real difference for millions of people living with conditions like atopic dermatitis, COPD, and asthma. We're accelerating toward Phase 3 and excited about what lies ahead. This is the kind of innovation our pipeline is built to deliver. More:

11,225 просмотров

Today marks a significant moment for Pfizer Inc. with the completion of our acquisition of Liate COHEN. Their highly differentiated candidates for obesity and cardiometabolic disease combined with Pfizer as a powerhouse in primary care, commercialization and manufacturing position us to reshape the treatment landscape. We’re not just participating in the obesity category. We aim to define it. Look forward to welcoming our new expert colleagues.

Today marks a significant moment for Pfizer Inc. with the completion of our acquisition of Liate COHEN. Their highly differentiated candidates for obesity and cardiometabolic disease combined with Pfizer as a powerhouse in primary care, commercialization and manufacturing position us to reshape the treatment landscape. We’re not just participating in the obesity category. We aim to define it. Look forward to welcoming our new expert colleagues.

18,652 просмотров

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Watching this ad filled me with pride and optimism about cancer breakthroughs—I’m grateful to have watched it with family, and glad they got my reaction when I made us watch it again!

Watching this ad filled me with pride and optimism about cancer breakthroughs—I’m grateful to have watched it with family, and glad they got my reaction when I made us watch it again!

53,792 просмотров • 1 год назад

Today marks a significant moment for Pfizer Inc. with the completion of our acquisition of Liate COHEN. Their highly differentiated candidates for obesity and cardiometabolic disease combined with Pfizer as a powerhouse in primary care, commercialization and manufacturing position us to reshape the treatment landscape. We’re not just participating in the obesity category. We aim to define it. Look forward to welcoming our new expert colleagues.

Today marks a significant moment for Pfizer Inc. with the completion of our acquisition of Liate COHEN. Their highly differentiated candidates for obesity and cardiometabolic disease combined with Pfizer as a powerhouse in primary care, commercialization and manufacturing position us to reshape the treatment landscape. We’re not just participating in the obesity category. We aim to define it. Look forward to welcoming our new expert colleagues.

18,652 просмотров • 6 месяцев назад

#PfizerProud of a strong year of execution and performance. Pfizer Inc.’s 2024 Annual Review shows how we met or beat our goals for each of our clear strategic priorities, setting the stage for even greater progress this year - including toward our goal of 8 cancer breakthroughs by 2030. ➡️ Read the 2024 Pfizer Annual Review:

#PfizerProud of a strong year of execution and performance. Pfizer Inc.’s 2024 Annual Review shows how we met or beat our goals for each of our clear strategic priorities, setting the stage for even greater progress this year - including toward our goal of 8 cancer breakthroughs by 2030. ➡️ Read the 2024 Pfizer Annual Review:

18,841 просмотров • 1 год назад

Больше нет контента для загрузки